{"created":"2023-06-19T11:24:44.959514+00:00","id":5511,"links":{},"metadata":{"_buckets":{"deposit":"6788121f-4fe8-4c6a-9f0d-f7adf75ebc65"},"_deposit":{"created_by":1,"id":"5511","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"5511"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:00005511","sets":["7","7:24"]},"author_link":["17224","17223","17225","17222","17226"],"item_5_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"41","bibliographicPageStart":"37","bibliographicVolumeNumber":"7","bibliographic_titles":[{"bibliographic_title":"Lower urinary tract symptoms"}]}]},"item_5_description_28":{"attribute_name":"識別番号 その他","attribute_value_mlt":[{"subitem_description":"PMID:26663650","subitem_description_type":"Other"}]},"item_5_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"OBJECTIVES:\n\\nTo evaluate the correlation of clinical and urodynamic parameters with bladder vascular resistance before and after dutasteride treatment in patients with lower urinary tract symptoms associated with benign prostatic enlargement.\nMETHODS:\n\\nA prospective study was conducted in 30 consecutive patients with benign prostatic enlargement who had not been satisfied with alpha-adrenergic antagonist monotherapy. Before and 24 weeks after dutasteride add-on treatment, we assessed International Prostate Symptom Score (IPSS), prostate volume (PV), urodynamic study and contrast-enhanced color Doppler ultrasonography to measure bladder vascular resistive index (RI).\nRESULTS:\n\\nTwenty-four weeks after dutasteride, PV significantly decreased from 68 ± 29 to 48 ± 28 mL (P < 0.001), and there was significant improvement of IPSS (from 18.8 ± 7.7 to 13.4 ± 7.2, P < 0.001). Urgency score of IPSS was also significantly improved from 2.3 ± 1.9 to 1.4 ± 1.4 (P < 0.01) after dutasteride. On pressure-flow study, bladder outlet obstruction index (BOOI) (from 58 ± 36 to 38 ± 27, P < 0.001) and detrusor pressure at Qmax (PdetQmax) (from 73 ± 34 to 54 ± 25 cmH2 O, P < 0.001) were significantly improved. RI significantly decreased after dutasteride (from 0.548 ± 0.069 to 0.486 ± 0.064, P < 0.001). In 20 patients with persistent urgency after dutasteride, RI was less improved than in another 10 patients without urgency (change of RI 0.045 ± 0.091 vs. 0.096 ± 0.042, P < 0.05). Post-treatment BOOI and PdetQmax in patients with persistent urgency was significantly higher than in those without urgency after dutasteride (BOOI: 46 ± 28 vs. 24 ± 20, P < 0.05, PdetQmax: 62 ± 26 vs. 40 ± 17 cmH2 O, P < 0.01).\nCONCLUSIONS:\n\\nReduction of obstruction and improvement of bladder ischemia might play an important role in a beneficial impact of dutasteride on overactive bladder symptoms.","subitem_description_type":"Abstract"}]},"item_5_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"text","subitem_description_type":"Other"}]},"item_5_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_5_relation_24":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/luts.12047","subitem_relation_type_select":"DOI"}}]},"item_5_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1757-5664","subitem_source_identifier_type":"ISSN"}]},"item_5_text_44":{"attribute_name":"ID(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"26663650"}]},"item_5_text_54":{"attribute_name":"閲覧数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"713"}]},"item_5_text_55":{"attribute_name":"ダウンロード数(XooNIps)","attribute_value_mlt":[{"subitem_text_value":"526"}]},"item_5_text_7":{"attribute_name":"著者 ローマ字","attribute_value_mlt":[{"subitem_text_value":"Wada, Naoki"},{"subitem_text_value":"Matsumoto, Seiji"},{"subitem_text_value":"Kita, Masafumi"},{"subitem_text_value":"Hashizume, Kazumi"},{"subitem_text_value":"Kakizaki, Hidehiro"}]},"item_5_version_type_38":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"和田, 直樹"},{"creatorName":"ワダ, ナオキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"17222","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"松本, 成史"},{"creatorName":"マツモト, セイジ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"17223","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"北, 雅史"},{"creatorName":"キタ, マサフミ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"17224","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"橋爪, 和純"},{"creatorName":"ハシヅメ, カズミ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"17225","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"柿崎, 秀宏"},{"creatorName":"カキザキ, ヒデヒロ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"17226","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-07-06"}],"displaytype":"detail","filename":"6522.pdf","filesize":[{"value":"313.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"6522.pdf","url":"https://asahikawa-med.repo.nii.ac.jp/record/5511/files/6522.pdf"},"version_id":"cf34239d-158b-429b-97ca-09f3686388ec"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"benign prostatic hyperplasia","subitem_subject_scheme":"Other"},{"subitem_subject":"bladder ischemia","subitem_subject_scheme":"Other"},{"subitem_subject":"dutasteride","subitem_subject_scheme":"Other"},{"subitem_subject":"lower urinary tract symptoms","subitem_subject_scheme":"Other"},{"subitem_subject":"overactive bladder","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement."}]},"item_type_id":"5","owner":"1","path":["6","7","24"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-08-16"},"publish_date":"2016-08-16","publish_status":"0","recid":"5511","relation_version_is_last":true,"title":["Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-06-19T12:19:36.577882+00:00"}